Hormone receptor negative HER2 positive breast cancer

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
11 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Taxane 2 substances
CDK inhibitor 2 substances
Antimetabolite 1 substance
Antibody-drug conjugate (ADC) 1 substance
Phase III: 1 Phase IV: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Gilead Sciences Inc. Commercial
    CAPECITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; SACITUZUMAB GOVITECAN
    2022-502593-17-00 11 countries 2023 n=428
    Ended

Phase IV

2 trials
  • GE Healthcare Limited Commercial
    IMP not specified
    2024-517400-11-00 1 country 2024 n=165
    Ended
  • Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic
    ABEMACICLIB; ANASTROZOLE; EXEMESTANE; GOSERELIN; LETROZOLE; LEUPRORELIN ACETATE; RIBOCICLIB
    2025-522848-40-00 1 country n=74
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Gilead Sciences Inc. Commercial 1 Phase III 0
GE Healthcare Limited Commercial 1 Phase IV 0
Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic 1 Phase IV 0
New trials by year
2023
1
2024
1
← All indication landscapes